AstraZeneca has received regulatory approval to market Trastuzumab Deruxtecan in India. This approval follows the drug’s existing approvals for the treatment of metastatic breast cancer and locally advanced or metastatic gastric cancer. Trastuzumab Deruxtecan is an antibody-drug conjugate used to treat certain types of cancers. The drug’s efficacy and safety profile were evaluated by the Indian regulatory authority, ensuring it meets established standards for clinical use. This represents a significant step in expanding Trastuzumab Deruxtecan’s availability to patients in India.
Posted inBusiness
AstraZeneca Secures Market Approval for Trastuzumab Deruxtecan in India
